The company reported the results from the (PROVE) retrospective study evaluating the real-world outcomes and safety of Fetroja in hospitalized patients with Gram-bacterial infections
The results showed that Fetroja achieved clinical cure in 63% of patients with Acinetobacter baumannii infections or Pseudomonas aeruginosa infections. In both Infections, 96% & 97% were resistant to carbapenems while the safety and tolerability results were consistent with the safety profile of Fetroja in clinical studies
79% of patients were alive and 21% of patients died within 30 days of starting Fetroja (30-day all-cause mortality), 1 patient experienced a serious ADR. In an analysis of early use experience, incl. compassionate use where patients had limited treatment options, 80% of patients reported clinical cures for difficult-to-treat gram- inf.
Ref: Shionogi | Image: Shionogi
